Blawg Search - Law Blogs, Lawyer Blogs, Legal Blogs Directory & Search Engine

... Williams -- Last Thursday, the Federal Circuit affirmed the decision of the District Court for the District of New Jersey denying a request by Altana Pharma and Wyeth (collectively "Altana") for a preliminary injunction to prevent Teva Pharmaceuticals ("Teva") from marketing a generic version of the antiulcer drug Protonix®. The active ingredient of Protonix® is the compound pantoprazole, which belongs to a class of compounds known as ...

... compound 12 as a lead compound for modification. So, the district court denied the motion for preliminary injunction. Altana Pharma AG and Wyeth went crying to the Court of Appeals for the Federal Circuit and the Federal Circuit said "too bad ... not granted; a balance of hardships tipping in its favor; and the injunction's favorable impact on the public interest. Altana argued that the district court was wrong for allowing the defendants to select compound 12 of the '518 patent as a lead compound ...

... denied Altana's motion for a preliminary injunction, finding a "substantial question" of whether the generic makers' obviousness defense would succeed. Because Altana didn't show that the defense lacked "substantial merit", the Federal Circuit held, the district court didn't abuse its discretion. Altana Pharma AG v. Teva Pharmaceuticals USA, Inc., No. 08-1039 (Fed. Cir. May 14, 2009). Blawgletter respectfully notes two things: ...

Altana Pharma AG and Wyeth v. Teva Pharms. USA, No. 04-2355 (D.N.J. 2007) Guest post by Robert S. Dailey Last Thursday, a federal district court ... on Thursday, Wyeth's stock fell by $1.82/share in late-day trading. UPDATE: In a research note Monday, pharma analyst Joe Tooley of A.G. Edwards said he expects Sun Pharma to receive final FDA approval today. Additionally, he stated that if both Teva and Sun decide to launch at-risk, the branded market for Protonix could contract as much as $500 ...